High Persistence Rate at One Year- Follow-Up of Subcutaneous Vedolizumab at Standard Dose after Switching Endovenous Vedolizumab, Even in Those Previously Intensified: Results of a Spanish Multicentre Observational Study.
Gastroenterologia y hepatologia（2025）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要